c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism

Parkinson’s disease (PD) is caused by a progressive degeneration of nigral dopaminergic cells leading to striatal dopamine deficiency. From the perspective of antiparkinsonian drug mechanisms, pharmacologic treatment of PD can be divided into symptomatic and disease-modifying (neuroprotective) thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yu, Yamamura, Yukio, Ogawa, Masatoshi, Tsuji, Ryosuke, Tsuchiya, Koichiro, Kasahara, Jiro, Goto, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250819/
https://www.ncbi.nlm.nih.gov/pubmed/30505273
http://dx.doi.org/10.3389/fphar.2018.01311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250819/
https://www.ncbi.nlm.nih.gov/pubmed/30505273
http://dx.doi.org/10.3389/fphar.2018.01311

Ejemplares similares